New drug combo shows promise for Tough-to-Treat bile duct cancer

NCT ID NCT05506943

Ongoing Disease control Sponsor: Compass Therapeutics Source: ClinicalTrials.gov ↗

First seen May 16, 2026 · Last updated May 22, 2026 · Updated 1 time

Summary

This study tests whether adding the experimental drug CTX-009 to standard chemotherapy (paclitaxel) helps adults with advanced bile duct, gallbladder, or ampullary cancer that has worsened after one prior treatment. About 168 participants will be randomly assigned to receive either the combination or chemotherapy alone. The main goal is to see if the combination shrinks tumors more effectively.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

AdventHealth Orlando

Orlando, Florida, 32804, United States
Cleveland Clinic

Cleveland, Ohio, 44195, United States
Columbia University

New York, New York, 10032, United States
Gabrail Cancer Center

Canton, Ohio, 44718, United States
Johns Hopkins University

Baltimore, Maryland, 21287, United States
Massachusetts General Hospital

Boston, Massachusetts, 02141, United States
Mayo Clinic Arizona

Phoenix, Arizona, 85054, United States
Mayo Clinic Jacksonville

Jacksonville, Florida, 32224, United States
Mayo Clinic Rochester

Rochester, Minnesota, 55905, United States
Memorial Medical Center

Las Cruces, New Mexico, 88011, United States
Montefiore Medical Center

The Bronx, New York, 10461, United States
Northwest Cancer Specialists, P.C.

Vancouver, Washington, 98684, United States
Northwestern University

Chicago, Illinois, 60611, United States
Ochsner Clinic Foundation

New Orleans, Louisiana, 70121, United States
Rocky Mountain Cancer Centers, LLP

Aurora, Colorado, 80012, United States
Roswell Park

Buffalo, New York, 14263, United States
Rutgers Cancer Institute

New Brunswick, New Jersey, 08854, United States
SCRI Oncology Partners

Nashville, Tennessee, 37203, United States
Stanford Medicine Cancer Center

Palo Alto, California, 94305, United States
Texas Oncology - Austin

Austin, Texas, 78705, United States
Texas Oncology - Baylor Charles A. Sammons Cancer Center

Dallas, Texas, 75246, United States
Texas Oncology - Dension

Denison, Texas, 75020, United States
Texas Oncology - Northeast Texas

Tyler, Texas, 75702, United States
Texas Oncology - San Antonio

San Antonio, Texas, 78217, United States
The University of New Mexico

Albuquerque, New Mexico, 87131, United States
The University of Texas MD Anderson Cancer Center

Houston, Texas, 77030, United States
University of Arizona

Tucson, Arizona, 85724-5024, United States
University of California San Francisco

San Francisco, California, 94143-1770, United States
University of Chicago

Chicago, Illinois, 60637, United States
University of Florida

Gainesville, Florida, 32611, United States
University of Southern California Norris Comprehensive Cancer Center

Los Angeles, California, 90033, United States
University of Tennessee Medical Center

Knoxville, Tennessee, 37920, United States
Virginia Mason Franciscan Health

Seattle, Washington, 98101, United States
Washington University School of Medicine, Siteman Cancer Center

St Louis, Missouri, 63110, United States

Conditions

Explore the condition pages connected to this study.

AMPULLARY CANCER BILIARY TRACT CANCER CHOLANGIOCARCINOMA GALL BLADDER CANCER